Wolfgang Miesbach: What Goes Wrong When Approved Gene Therapies Get Withdrawn?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Ana Hidalgo-Simon and Claire Booth, published in Blood ICT:
”Gene therapy approved. Gene therapy withdrawn. What went wrong?
38% of all approved ATMPs in the EU have been withdrawn – not because they failed, but because the commercial model collapsed.
Zynteglo for β-thalassemia had orphan designation, PRIME status, conditional approval, accelerated assessment – and was still pulled from the market in 2022 when reimbursement negotiations failed.
Beqvez for haemophilia B: same story.
Why?
- Most gene therapies are born in academia – outstanding science, but commercial planning is not the focus
- Health systems run on chronic care budgets – a large one-off payment for a cure simply doesn’t fit
- Post-approval requirements aren’t scaled for ultrarare diseases, making the economics brutal even after approval
What the authors propose is worth taking seriously:
- Charitable foundations as marketing authorization holders — Telethon took over Strimvelis from Orchard Therapeutics in 2023, the first such transfer for an ATMP
- The AGORA Foundation enabling cross-border access to proven therapies across Europe
- Public benefit corporations like Rarity (US) advancing ADA-SCID gene therapy
- Hospital exemption pathways as a structured route for ultrarare diseases
- EU joint clinical assessments now operational from 2025 — a first step toward harmonized reimbursement
For haemophilia, this is not hypothetical – it is happening now.
The lessons from immune deficiency gene therapy are directly relevant to where we stand with hemophilia A and B gene therapies today.
Congratulations to the authors Ana Hidalgo-Simon and Claire Booth.”
Title: Advancing ATMPs for orphan diseases: redefining the roles of pharmaceutical companies and academia
Authors: Ana Hidalgo-Simon, Claire Booth
Read the Full Article on Blood ICT
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 1, 2026, 22:00Aurelio Maggio: Congratulations to Mariasanta Napolitano on Her 1st Year Leading the Haematology and Rare Disease Uni tat ”V. Cervello” Hospital
-
Apr 1, 2026, 21:21Shubham Misra: CCL2 As a Potential Biomaker for Post-Stroke Seizures, Epileptiform Discharges and Mortality
-
Apr 1, 2026, 21:00Johns Hopkins All Children’s Hospital Becomes The 1st U.S Pediatric VTE Center of Excellence – NBCA
-
Apr 1, 2026, 20:17Aswin K Mohan: The Most Common Misconceptions on Blood Donation
-
Apr 1, 2026, 19:26Thomas Vogl: Simon Bernatz Demonstrates that The Thymus Plays a Crucial Role in Health, Immune Resilience, and Longevity
-
Apr 1, 2026, 18:46Fritz Torto: Why Every Survivor Has a Duty to Build a Stronger Future for Others
-
Apr 1, 2026, 18:08Joshua Muia: Our Latest Review on the Proatherogenic Metalloprotease ADAMTS7
-
Apr 1, 2026, 17:47Akshaya Sharon: Qfitlia as a Shift in Treatment Strategy for Hemophilia A and B
-
Apr 1, 2026, 17:21Antonio Pineda Guerrero: Elevated Lp(a) Raises VTE Risk But Only in the Right Hormonal Context